
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Boston - Therapeutic strategies for patients with recalcitrant or severe atopic dermatitis (AD) should include a plan to manage acute flares but also maintain disease control over the longer term, said Seth J. Orlow, M.D., Ph.D., at the American College of Allergy, Asthma, & Immunology's Derm Fest here.